<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/1C5B57EF-0604-4823-B8D1-61358B1C2B14"><gtr:id>1C5B57EF-0604-4823-B8D1-61358B1C2B14</gtr:id><gtr:name>Myodopa Limited</gtr:name><gtr:address><gtr:line1>C/O Cmb Partnership Limited Chapel House, 1 Chapel Street</gtr:line1><gtr:city>Guildford</gtr:city><gtr:postCode>GU1 3UH</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1C5B57EF-0604-4823-B8D1-61358B1C2B14" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>1C5B57EF-0604-4823-B8D1-61358B1C2B14</gtr:id><gtr:name>Myodopa Limited</gtr:name><gtr:address><gtr:line1>C/O Cmb Partnership Limited Chapel House, 1 Chapel Street</gtr:line1><gtr:city>Guildford</gtr:city><gtr:postCode>GU1 3UH</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>105000.0</gtr:offerGrant><gtr:projectCost>150000.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/97A4F59C-CBEB-47B4-BE10-E9A08C8FCCFC"><gtr:id>97A4F59C-CBEB-47B4-BE10-E9A08C8FCCFC</gtr:id><gtr:firstName>Mike</gtr:firstName><gtr:surname>McDonald</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=133348"><gtr:id>4EA2A9B1-1205-4315-8C56-9014195A5CA3</gtr:id><gtr:title>Myodopa: Treating Parkinsons diease by transducing constant peripheral secretion of l-dopa</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Feasibility Studies</gtr:grantCategory><gtr:grantReference>133348</gtr:grantReference><gtr:abstractText>The objective is to develop a gene therapy product capable of enabling lifelong secretion of constant therapeutic levels of l-dopa into the peripheral circulation as treatment for moderate or severe Parkinson?s disease. Success will be producing plasma levels similar to those produced by therapeutic doses of Duodopa. Duodopa delivers stable plasma levels of l-dopa using a pump to deliver drug directly to the lower small intestine via a PEG tube passing through the abdominal wall. Efficacy is superior to oral l-dopa and there is a lower incidence of on/off fluctuations and dyskinesia ? both achieved by avoiding the fluctuating plasma levels which complicate oral dosage. The lifelong requirement for a pump and PEG tube causes significant adverse events and is impractical. Despite this, sales of Duodopa( are forecast to reach $580 million in 2019. Myodopa Limited has filed a patent application for the use of viral and non-viral vectors to achieve lifelong stable therapeutic plasma levels of l-dopa by endogenous secretion from muscles or liver. If successful this innovative approach would transform the treatment of PD. The program will develop and compare different constructs and select the candidate delivering optimal plasma levels of l-dopa and the lowest bulk manufacturing costs.</gtr:abstractText><gtr:fund><gtr:end>2018-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2017-12-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>105000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">133348</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>